Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 9481Neoplasms 6589Prostatic Neoplasms 4399Colorectal Neoplasms 3978Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Leukemia, Myeloid, Acute 2265Multiple Myeloma 2121Stomach Neoplasms 2109Neoplasm Metastasis 1911Head and Neck Neoplasms 1870Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1730Brain Neoplasms 1702Rectal Neoplasms 1676Melanoma 1656Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1486Esophageal Neoplasms 1312Glioblastoma 1308Lymphoma, Non-Hodgkin 1205Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

Specimen Handling 1Nivolumab 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Resectable Hepatocellular Carcinoma × Clear all
NCT04856046 2026-04-24

Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer

Mayo Clinic

Active not recruiting
36 enrolled
Gastrointestinal

Resectable Hepatocellular Carcinoma

NCT04965714 2023-02-16

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Resectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡